Business
Viveve(R) to Announce Financial Results for Second Quarter Ending June 30, 2016
Viveve(R) to Announce Financial Results for Second Quarter Ending June 30, 2016.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve(R) to Announce Financial Results for Second Quarter Ending June 30, 2016\n\nViveve(R) to Announce Financial Results for Second Quarter Ending June 30, 2016\n\nSUNNYVALE, CA--(Marketwired - August 04, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the second quarter ended June 30, 2016 on Thursday, August 11, 2016 after market close. The Company will also host a live conference call to discuss these financial results and provide an update on corporate developments. Participating on the call will be Patricia Scheller, chief executive officer, and Scott Durbin, chief financial officer. Following management's formal remarks, there will be a question and answer session.The conference call is scheduled to begin at 5:00 p.m. ET on August 11, 2016. The conference call can be accessed at http://dpregister.com/10090630. The dial-in telephone number will be provided upon registration, either in advance of or at the time of the conference call. The conference call will be archived on the company's website at http://ir.viveve.com/ir-calendar.About ViveveViveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.Safe Harbor StatementAll statements in this press release that are not based on historical f...